Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 1/1/05 → 12/31/06 |
Funding
- AstraZeneca Pharmaceuticals AB: $15,830.00
Randomized Double Blind Placebo Controlled Multicent Phase III Study of Rosuvastatin (CRESTOR) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects
- Anderson, James (PI)
- Reynolds, L (CoI)
- Tannock, Lisa (CoI)